Dan Scholefield
Mr. Scholefield is a co-founder and managing member of Genautica. He is currently taking on the role as Co-Chairman of the Board of Diagnomics. He serves as a trustee, managing several private family office operations with a tenure that spans over 20 years. He is also a principal at Scoplex. He brings an experience level and successful investment track record that includes leading due diligence efforts, closing deals and managing investment ventures in various technologies, including biotech, oil and gas, real estate, as well as equity markets, PIPE transations, and derivatives.
Mr. Scholefield and Dr. Stefan Gruenwald co-founded Genautica LLC, as a holding company to identify, invest in, incubate and integrate ready-for-market technologies in biotech, oil and gas. Mr. Scholefield holds a degree in mechanical aerospace engineering from the University of Utah.
Stefan Gruenwald, MD, PhD
Dr. Gruenwald is a co-founder and managing member of Genautica. Dr. Gruenwald is also the president and a co-founder of Diagnomics. Dr. Gruenwald's career in Life Science spans more than two decades. He received his MD / PhD at the Johann-Wolfgang Goethe University in Frankfurt, Germany. He later completed his post-doctoral training at the Scripps Research Institute and the University of California San Diego (UCSD).
In 1991, Dr. Gruenwald joined the newly formed PharMingen (now a part of BD Bioscience), which has become one of the most successful San Diego based biotech companies. At PharMingen, Dr. Gruenwald established and maintained a research team of 155 scientists. His R&D lab cloned over 1,300 genes and expressed more than 800 proteins in various protein expression systems. Dr. Gruenwald holds three patents, based on technologies developed at PharMingen. Dr. Gruenwald is also very experienced in M&A within the life sciences arena. In 1997, he was instrumental in the $75M sale of PharMingen to Fortune 100 Company, Becton Dickinson. He is fluent in English and German.
Min Seob Lee, PhD
Dr. Min Seob Lee is a co-founder of Diagnomics. He is also the co-founder and co-CEO of the Korean EONE-Diagnomics Genome Center (EDGC) and has extensive experience in the biotech industry. He worked for many decades in diagnostics and therapeutic settings, with specific expertise in genomics, pharmacogenomics, bioinformatics and diagnostic development. He is a world leader in Genomics, Diagnostics and associated applications for personalized medicine. Prior to Diagnomics, he was a vice president of the Theragen Bio Institute and CTO of GenomeCare and Precision Biocount. He also held several positions of increasing responsibility at Sequenom in Molecular Medicine and Diagnostic Dvelopment Departments. Dr. Lee also served as a Senior Manager in CLIA and GLP laboratories performing high-throughput genome sequencing and genotyping at Genaissance Pharmaceuticals in Connecticut.
Dr. Lee published numerous articles and has been granted several important genomics and molecular diagnostics patents. He conducted his post-doctoral fellowship at Harvard Medical School, and received a Ph.D. from the City of Hope National Medical Center and Beckman Research Institute in California.
Shin Shang Cheol
Mr. Shin Shang Cheol is co-founder and co-CEO of the Korean EONE-Diagnomics Genome Center (EDGC) in Korea. He graduated from the Yonsei University and has worked for over 20 years at Samsung Securities. His professional experience which he gained from his work at Samsung Securities is very diverse, especially in the wholesale and retail business sector. He was also an executive in Samsung's Management Support division and his office was located in the Investment Banking Business headquarter.
Mr. Shin’s working experience in Investment Banking involves interaction with hundreds of companies, and he focused on IPO, M&A, privatization of the public corporation, and capital raises. He has an excellent understanding for various issues and solutions for corporations at various stages of their corporate life cycle.